Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0026764 (multiple myeloma)
 36,148 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A large excess of non-Hodgkin's lymphoma has been documented in renal transplant patients and may be related to immunosuppressive therapy, persistent antigenic challenge from the graft, or both. To determine whether immuno-suppression resulting from chronic renal failure is associated with an elevated risk of certain tumors such as non-Hodgkin's lymphoma, the authors studied cancer incidence in a national cohort of 28,049 patients in the United States with chronic renal failure who received maintenance dialysis for at least six months (totaling 66,706 person-years of observation). Compared with national incidence rates, the relative risk (RR) of cancer was 0.9 (excluding nonmelanoma skin cancer, multiple myeloma, kidney cancer, and uterine cervix cancer). Moderate excesses of leukemia, non-Hodgkin's lymphoma, Hodgkin's disease, thyroid cancer, and biliary tract cancer were found, but were not statistically significant for both sexes combined. A significantly elevated risk of non-Hodgkin's lymphoma among patients with chronic glomerulonephritis (RR = 2.6) accounted for the excess observed in the total series, raising the possibility of factors specific to this disease.
 ...
PMID:Cancer in patients receiving long-term dialysis treatment. 311 33

The First National Health and Nutrition Examination Survey (NHANESI), conducted in 1971-1975, included a cohort of 6913 adults for whom history of smoking, allergies, and other factors was obtained. These persons were traced (with 93% success) approximately 10 years later by the NHANESI Epidemiologic Followup Survey, and incidence of malignancy in the interim period was determined. Primary allergy variables were physician-diagnosed asthma, hay fever, hives, food allergy, or other allergies. Excluded were persons with a prior history of cancer and cases of nonmelanoma skin cancer. After adjustment by logistic regression for age, sex, race, and smoking history, allergic history was found to increase the risk of subsequent malignancy (risk odds ratio = 1.40, 95% confidence interval = 1.10-1.77). The specific allergy type with the strongest cancer risk was hives. The cancer group with the strongest allergy association was lymphatic-hematopoietic (leukemia, lymphoma, myeloma). The risk odds ratio of developing leukemia, lymphoma, or myeloma for persons with hives history was 7.89 (95% CI = 3.13-19.89). These findings suggest that a history of allergy does not protect against subsequent cancer, and may be a risk factor. The possibility is raised that a history of hives may be a particular risk factor for lymphatic-hematopoietic malignancies.
 ...
PMID:Allergy and risk of cancer. A prospective study using NHANESI followup data. 338 43

The Swedish Cancer-Environment Register was used to study time-related trends in relative risks (RRs) of cancer between 1961 and 1979 in a cohort of 254,417 Swedish men who were employed in agriculture in 1960. The reference cohort consisted of 1,725,845 Swedish men who were gainfully employed in economic activities other than agriculture or forestry in 1960. Altogether 24,763 cancers were observed in the study cohort and 146,900 in the reference cohort, giving an estimated RR for the entire study period of 0.82 (95% confidence interval: 0.81-0.83). The RR for all sites combined increased from 0.80 in 1961-73 to 0.84 in 1974-79 (P less than .01). The RR also increased over time for primary liver cancer (P less than .01), prostate cancer (P less than .01), cancer of other genital organs (P less than .01), cancer of urinary organs (P less than .01), lip cancer (P less than .05), and cancer of the nose and nasal cavities (P less than .05). For most of these sites the RR remained lower than unity. For prostate cancer, however, the RR was unity at the end of the study period. A decrease in the RR over time was observed for skin carcinomas of the trunk and limbs (P less than .05) and malignant tumors of the nervous system (P less than .05). For 27 of the 48 analyzed tumor sites the RR for the entire period 1961-79 was significantly lower than unity. The lowest RRs were seen for cancer of the pleura (0.25), cancer of the larynx (0.35), lung cancer (0.36), cancer of the hypopharynx (0.36), cancer of the floor of mouth (0.40), primary liver cancer (0.44), and cancer of the kidney pelvis (0.49). RRs significantly higher than unity were found for cancer of the lip (1.92), malignant melanoma, and carcinoma of the skin in the head and neck region (1.39 and 1.15, respectively), multiple myeloma (1.20), and cancer of the stomach (1.07).
 ...
PMID:Trends in cancer risks among Swedish agricultural workers. 346 7

There is increasing evidence that vitamin D reduces the risk of many types of cancer. Geographic variations in cancer mortality rates in Spain are apparently linked to variations in solar ultraviolet (UV) irradiances and other factors. Cancer mortality rates for 48 continental Spanish provinces for 1978-1992 were used in linear regression analyses with respect to mortality rates for latitude (an index of solar UVB levels), skin cancer (an index of high cumulative UVB irradiance), melanoma (an index related to solar UV irradiance and several other factors) and lung cancer (an index of cumulative effects of smoking). The 9 cancers with mortality rates significantly correlated with latitude for 1 or both sexes were brain, gastric, melanoma, nonmelanoma skin cancer (NMSC), non-Hodgkin's lymphoma (NHL), pancreatic, pleural, rectal and thyroid cancer. Inverse correlations with latitude were found for laryngeal, lung and uterine corpus cancer. The 17 cancers inversely correlated with NMSC are bladder, brain, breast, colon, esophageal, gallbladder, Hodgkin's lymphoma, lung, melanoma, multiple myeloma, NHL, ovarian, pancreatic, pleural, rectal, thyroid and uterine corpus cancer. The 16 correlated with melanoma are bladder, brain, breast, colon, gallbladder, leukemia, lung, multiple myeloma, NHL, ovarian, pancreatic, pleural, prostate, rectal, renal and uterine corpus cancer. The results for lung cancer were in accordance with the literature. These results provide more support for the UVB/vitamin D/cancer hypothesis and indicate a new way to investigate the role of solar UV irradiance on cancer risk. They also provide more evidence that melanoma and NMSC have different etiologies.
 ...
PMID:An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. 1714 99

Using population-based data from Sweden, we identified all multiple myeloma (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS) patients diagnosed between 1986 and 2005. We calculated standardized incidence rates (SIRs) for all subsequent hematologic and nonhematologic malignancies for MM patients diagnosed before/after 1995 (introduction of high-dose melphalan/autologous stem cell transplantation [HDM-ASCT]) and 2000 (introduction of immunomodulatory drugs [IMiDs]), respectively. MM patients had an 11.51-fold (95% confidence interval: 8.19-15.74) increased risk of acute myeloid leukemia (AML)/myelodysplastic syndromes (MDS); risk was very similar before/after 1995 and 2000, respectively. MGUS patients had an 8.01-fold (5.40-11.43) increased risk of AML/MDS. Risk was confined to IgG/IgA, while no IgM MGUS patients developed AML/MDS; patients with monoclonal-protein (M-protein) concentrations > 1.5 g/dL (SIR = 11.12; 3.61-25.96) had higher risk than those < 1.5 g/dL (SIR = 4.67; 1.71-10.16). An excess risk of nonmelanoma skin cancer was observed subsequent to both MM (SIR = 2.22; 1.74-2.80) and MGUS (SIR = 3.30; 2.76-3.90). Our novel observations of an excess risk for AML/MDS following IgG/IgA (but not IgM) MGUS, and the highest risk associated with M-protein concentrations > 1.5 g/dL, support a role for nontreatment-related factors in plasma cell dyscrasias. AML/MDS risk following MM was the same before/after the introduction of HDM-ASCT. Longer follow-up is needed to characterize second tumor risks in the IMiD era.
 ...
PMID:Risk of acute myeloid leukemia and myelodysplastic syndromes after multiple myeloma and its precursor disease (MGUS). 2199 30